Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists
N04BC09 Rotigotine
D05768 Rotigotine (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antiparkinson Agents
Dopamine Agonists
Rotigotine
D05768 Rotigotine (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
116 Antiparkinsonian agents
1169 Others
D05768 Rotigotine (JAN/USAN/INN)
119 Miscellaneous
1190 Miscellaneous
D05768 Rotigotine (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
D05768 Rotigotine
DG01967 Antiparkinson agent
D05768 Rotigotine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
D05768 Rotigotine
DG01639 CYP2C19 substrate
D05768 Rotigotine
DG02971 SULT substrate
D05768 Rotigotine
DG02924 UGT substrate
DG03188 UGT1A9 substrate
D05768 Rotigotine
DG03187 UGT2B15 substrate
D05768 Rotigotine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D05768 Rotigotine (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05768
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05768
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05768
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05768
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D05768